VSN16R: Phase II started

Canbex began a double-blind, placebo-controlled, dose-escalation, U.K. Phase II trial to evaluate 50-400 mg oral VSN16R daily or twice daily for 26 days in about 142 patients. Ipsen Group (Euronext:I...